Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
Am J Trop Med Hyg ; 102(5): 1056-1063, 2020 05.
Article in English | MEDLINE | ID: mdl-32100686

ABSTRACT

Artemether-lumefantrine (AL) is the first-line treatment for uncomplicated Plasmodium falciparum infection in Colombia. To assess AL efficacy for uncomplicated falciparum malaria in Quibdo, Choco, Colombia, we conducted a 28-day therapeutic efficacy study (TES) following the WHO guidelines. From July 2018 to February 2019, febrile patients aged 5-65 years with microscopy-confirmed P. falciparum mono-infection and asexual parasite density of 250-100,000 parasites/µL were enrolled and treated with a supervised 3-day course of AL. The primary endpoint was adequate clinical and parasitological response (ACPR) on day 28. We attempted to use polymerase chain reaction (PCR) genotyping to differentiate reinfection and recrudescence, and conducted genetic testing for antimalarial resistance-associated genes. Eighty-eight patients consented and were enrolled; four were lost to follow-up or missed treatment doses. Therefore, 84 (95.5%) participants reached a valid endpoint: treatment failure or ACPR. No patient remained microscopy positive for malaria on day 3, evidence of delayed parasite clearance and artemisinin resistance. One patient had recurrent infection (12 parasites/µL) on day 28. Uncorrected ACPR rate was 98.8% (83/84) (95% CI: 93.5-100%). The recurrent infection sample did not amplify during molecular testing, giving a PCR-corrected ACPR of 100% (83/83) (95% CI: 95.7-100%). No P. falciparum kelch 13 polymorphisms associated with artemisinin resistance were identified. Our results support high AL efficacy for falciparum malaria in Choco. Because of the time required to conduct TESs in low-endemic settings, it is important to consider complementary alternatives to monitor antimalarial efficacy and resistance.


Subject(s)
Antimalarials/therapeutic use , Artemether, Lumefantrine Drug Combination/therapeutic use , Malaria, Falciparum/drug therapy , Adolescent , Adult , Age Factors , Aged , Antimalarials/administration & dosage , Artemether, Lumefantrine Drug Combination/administration & dosage , Child , Child, Preschool , Colombia , Drug Resistance/genetics , Female , Humans , Male , Middle Aged , Plasmodium falciparum/drug effects , Plasmodium falciparum/genetics , Polymorphism, Single Nucleotide/genetics , Treatment Outcome , Young Adult
2.
Int J Environ Res Public Health ; 11(8): 8301-18, 2014 Aug 15.
Article in English | MEDLINE | ID: mdl-25153463

ABSTRACT

Leptospirosis is an epidemic-prone zoonotic disease that occurs worldwide, with more than 500,000 human cases reported annually. It is influenced by environmental and socioeconomic factors that affect the occurrence of outbreaks and the incidence of the disease. Critical areas and potential drivers for leptospirosis outbreaks have been identified in Nicaragua, where several conditions converge and create an appropriate scenario for the development of leptospirosis. The objectives of this study were to explore possible socioeconomic variables related to leptospirosis critical areas and to construct and validate a vulnerability index based on municipal socioeconomic indicators. Municipalities with lower socioeconomic status (greater unsatisfied basic needs for quality of the household and for sanitary services, and higher extreme poverty and illiteracy rates) were identified with the highest leptospirosis rates. The municipalities with highest local vulnerability index should be the priority for intervention. A distinction between risk given by environmental factors and vulnerability to risk given by socioeconomic conditions was shown as important, which also applies to the "causes of outbreaks" and "causes of cases".


Subject(s)
Disease Outbreaks , Leptospirosis/epidemiology , Humans , Nicaragua/epidemiology , Socioeconomic Factors
3.
Int J Environ Res Public Health ; 9(11): 3883-910, 2012 Oct 26.
Article in English | MEDLINE | ID: mdl-23202822

ABSTRACT

Leptospirosis is an epidemic-prone zoonotic disease that occurs worldwide. In Central America, leptospirosis outbreaks have been reported in almost all countries; Nicaragua in particular has faced several outbreaks. The objective of this study was to stratify the risk and identify "critical areas" for leptospirosis outbreaks in Nicaragua, and to perform an exploratory analysis of potential "drivers". This ecological study includes the entire country (153 municipalities). Cases from 2004 to 2010 were obtained from the country's health information system, demographic and socioeconomic variables from its Census, and environmental data from external sources. Criteria for risk stratification of leptospirosis were defined. Nicaragua reported 1,980 cases of leptospirosis during this period, with the highest percentage of cases (26.36%) in León, followed by Chinandega (15.35%). Among the 153 municipalities, 48 were considered critical areas, 85 were endemic and 20 silent. Using spatial and statistical analysis, the variable presenting the most evident pattern of association with critical areas defined by top quintile of incidence rate is the percentage of municipal surface occupied by the soil combination of cambisol (over pyroclastic and lava bedrock) and andosol (over a volcanic ashes foundation). Precipitation and percentage of rural population are also associated with critical areas. This methodology and findings could be used for Nicaragua's Leptospirosis Intersectoral Plan, and to identify possible risk areas in other countries with similar drivers.


Subject(s)
Disease Outbreaks , Leptospirosis/epidemiology , Planning Techniques , Humans , Nicaragua/epidemiology , Risk Factors
4.
Am J Trop Med Hyg ; 85(3): 573-8, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21896825

ABSTRACT

We evaluated the efficacy and effectiveness of mefloquine (MQ) plus artesunate (AS) to treat patients with uncomplicated malaria in the Peruvian Amazon Basin in April 2005-March 2006. Patients ≥ 1 year of age with fever (axillary temperature ≥ 37.5°C) or history of fever and Plasmodium falciparum monoinfection were included. Patients received antimalarial treatment with MQ (12.5 mg/kg/day for two days) and AS (4.0 mg/kg/day for three days) either by directly observed therapy or without directly observed therapy. After a 28-day follow-up, treatment efficacy and effectiveness were assessed on the basis of clinical and parasitologic outcomes. Ninety-six patients were enrolled in each study group; nine patients were lost to follow-up. All patients, except for one in the observed group, demonstrated adequate clinical and parasitologic response; none had detectable parasitemia on day 3. The efficacy of MQ + AS efficacy was 98.9% (95% confidence interval = 94.1-100.0%) and the effectiveness was 100.0% (95% confidence interval = 95.9-100.0%). Our study shows that MQ + AS is highly efficacious in the Peruvian Amazon.


Subject(s)
Antimalarials/therapeutic use , Malaria, Falciparum/drug therapy , Adolescent , Adult , Aged , Animals , Child , Child, Preschool , Directly Observed Therapy , Drug Therapy, Combination , Female , Humans , Malaria, Falciparum/epidemiology , Male , Middle Aged , Peru/epidemiology , Plasmodium falciparum , Young Adult
5.
Am J Trop Med Hyg ; 79(1): 42-4, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18606762

ABSTRACT

In 2001, Peru changed its treatment policy for uncomplicated Plasmodium falciparum malaria on the northern Pacific Coast to sulfadoxine-pyrimethamine with atresunate (SP-AS). Because Peru was the first country in the Americas to adopt this combination therapy, we established a surveillance system in the region to assess the frequency of new or worsening symptoms after starting therapy. Over a period of two years, 1,552, or approximately two-thirds of all patients with uncomplicated P. falciparum malaria who had received SP-AS on the northern coast were followed up. Of these, 8.8% reported at least one adverse effect, with the most common being vomiting, nausea, headache, abdominal pain, dizziness, and fever; no severe adverse effects related to SP-AS therapy were identified. Treatment of uncomplicated malaria with SP-AS was associated with a low frequency of mild adverse effects in Peru, and therefore should be considered as a first-line therapy in areas of the Americas where SP efficacy is still high.


Subject(s)
Antimalarials/therapeutic use , Artemisinins/therapeutic use , Drug Therapy, Combination , Malaria, Falciparum/drug therapy , Malaria, Falciparum/epidemiology , Pyrimethamine/therapeutic use , Sulfadoxine/therapeutic use , Antimalarials/administration & dosage , Antimalarials/adverse effects , Artemisinins/administration & dosage , Artemisinins/adverse effects , Artesunate , Drug Combinations , Humans , Peru/epidemiology , Pyrimethamine/administration & dosage , Pyrimethamine/adverse effects , Sulfadoxine/administration & dosage , Sulfadoxine/adverse effects
6.
Am J Trop Med Hyg ; 76(4): 614-8, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17426158

ABSTRACT

High levels of Plasmodium falciparum resistance to both chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) have been documented throughout the Amazon Basin of South America. Because of reports about the persistent efficacy of both of these drugs in the northwestern Peruvian Amazon region, we carried out an evaluation of the therapeutic efficacy of chloroquine (25 mg/kg) and SP (25 mg/kg of the sulfadoxine component) for the treatment of uncomplicated P. falciparum infections at two sites: Ullpayacu and Pampa Hermoza/Alianza. A total of 111 patients were enrolled. Only 5 (14.3%) of the 35 patients who received CQ had an adequate clinical and parasitologic response (ACPR). Six subjects (17%) had early treatment failure, 1 (2.9%) had late clinical failure, and 23 (65.7%) had late parasitologic failure (LPF). Of the subjects treated with SP, 92.3% had ACPR and 7.7% had LPF. Based on these findings, it is clear that there are at least limited areas within the Peruvian Amazon region where P. falciparum strains continue to be sensitive to SP.


Subject(s)
Antimalarials/pharmacology , Drug Resistance/genetics , Malaria, Falciparum/epidemiology , Malaria, Falciparum/parasitology , Plasmodium falciparum/drug effects , Adolescent , Adult , Animals , Child , Child, Preschool , Chloroquine/pharmacology , Drug Combinations , Female , Humans , Malaria, Falciparum/drug therapy , Male , Middle Aged , Peru/epidemiology , Pyrimethamine/pharmacology , Sulfadoxine/pharmacology
7.
Am J Trop Med Hyg ; 72(5): 568-72, 2005 May.
Article in English | MEDLINE | ID: mdl-15891131

ABSTRACT

To assist the Peruvian Ministry of Health in modifying the malaria treatment policy for their north Pacific coastal region, we conducted an in vivo efficacy trial of sulfadoxine-pyrimethamine (SP) and SP plus artesunate (SP-AS) for the treatment for uncomplicated Plasmodium falciparum infections. A total of 197 patients were randomized to therapy with either SP (25 mg/kg of the sulfadoxine component in a single dose on day 0) or a combination of SP plus AS (4 mg/kg on days 0, 1, and 2) and were followed for 28 days for symptoms and recurrence of parasitemia. No statistically significant differences between the two groups were observed on enrollment with respect to age, sex, history of malaria, or geometric mean parasite density. A total of 185 subjects completed the 28-day follow-up. Of the 91 subjects treated with SP alone, two had recurrences of parasitemia on day 7 and one on day 21. Of the 94 subjects treated with SP-AS, one had a recurrence of parasitemia on day 21. Fever and asexual parasite density decreased significantly more rapidly and the proportion of patients with gametocytemia on days 3-28 was significantly lower in subjects treated with combination therapy than in those who received SP alone. No severe adverse drug reactions were observed; however, self-limited rash and pruritus were significantly more common and an exacerbation of nausea, vomiting, and abdominal pain were observed significantly more frequently among patients who had received SP-AS. These results have contributed to a National Malaria Control Program decision to change to SP-AS combination therapy as the first-line treatment for uncomplicated P. falciparum malaria in northern coastal Peru in November 2001, making Peru the first country in the Americas to recommend this combination therapy.


Subject(s)
Antimalarials/therapeutic use , Artemisinins/therapeutic use , Malaria, Falciparum/drug therapy , Pyrimethamine/therapeutic use , Sesquiterpenes/therapeutic use , Sulfadoxine/therapeutic use , Adolescent , Adult , Antimalarials/administration & dosage , Antimalarials/adverse effects , Artemisinins/administration & dosage , Artemisinins/adverse effects , Artesunate , Child , Drug Combinations , Drug Therapy, Combination , Female , Humans , Male , Peru , Pyrimethamine/administration & dosage , Pyrimethamine/adverse effects , Sesquiterpenes/administration & dosage , Sesquiterpenes/adverse effects , Sulfadoxine/administration & dosage , Sulfadoxine/adverse effects
9.
Rev. Soc. Bras. Med. Trop ; 37(3): 279-281, maio-jun. 2004. mapas, tab
Article in English | LILACS | ID: lil-360419

ABSTRACT

Testes in vivo foram realizados para avaliar resistência a drogas antimalária, em pessoas com malária não complicada, causada por Plasmodium falciparum, numa região isolada da Bacia Amazônica, na fronteira com o Brasil e a Colômbia. Os testes mostraram resistência >50 por cento RII/RIII a sulfadoxina-pirimetamina, mas não evidenciaram resistência a mefloquina.


Subject(s)
Humans , Animals , Male , Female , Antimalarials , Malaria, Falciparum , Mefloquine , Plasmodium falciparum , Drug Combinations , Drug Resistance , Peru , Treatment Outcome
10.
Trop Med Int Health ; 9(2): 217-21, 2004 Feb.
Article in English | MEDLINE | ID: mdl-15040558

ABSTRACT

We assessed the efficacy of mefloquine monotherapy and mefloquine-artesunate (MQ-AS) combination therapy for the treatment of Plasmodium falciparum malaria at four sites in the Bolivian Amazon region. Patients with uncomplicated P. falciparum infections between 5 and 60 years of age were randomly assigned to be treated with either MQ (15 mg/kg in a single oral dose) or MQ (15 mg/kg) plus AS (4 mg/kg daily for 3 days). A total of 143 patients were enrolled and followed for 28 days. None of the 73 patients who received MQ alone or the 70 patients who received MQ-AS combination therapy had recurrences of parasitaemia during the 28-day follow-up period. Asexual parasite densities fell significantly more rapidly and the proportion of patients with gametocytes was significantly lower on days 7-28 in patients treated with MQ-AS than in those treated with MQ alone. All patients tolerated the medications well. After this study, the Bolivian Ministry of Public Health changed its treatment policy for uncomplicated P. falciparum malaria in the Amazon region to combination therapy with MQ-AS to slow or prevent the development of resistance.


Subject(s)
Antimalarials/therapeutic use , Artemisinins/therapeutic use , Malaria, Falciparum/drug therapy , Mefloquine/therapeutic use , Sesquiterpenes/therapeutic use , Adolescent , Adult , Antimalarials/adverse effects , Artemisinins/adverse effects , Artesunate , Bolivia , Child , Child, Preschool , Drug Therapy, Combination , Female , Humans , Malaria, Falciparum/blood , Male , Mefloquine/adverse effects , Middle Aged , Parasitemia/drug therapy , Sesquiterpenes/adverse effects , Treatment Outcome
11.
Am J Trop Med Hyg ; 69(5): 548-52, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14695094

ABSTRACT

Reports from several sites in South America suggest the presence of isolated cases of chloroquine-resistant Plasmodium vivax malaria. To investigate the possibility of chloroquine-resistant P. vivax in Peru, we conducted 28-day in vivo drug efficacy trials at three sites in the Amazon region and one site on the northern Pacific Coast between 1998 and 2001. A total of 242 patients between the ages of 2 and 60 years were enrolled (177 from the Amazon region and 65 from the northern coast). All subjects received directly observed therapy with chloroquine, 25 mg/kg, over a three-day period. On enrollment, 49% had a documented fever and 96% had a history of fever; their geometric mean parasite density was 5,129 parasites/microL. A total of 212 (88%) of the 242 subjects completed their 28-day follow-up. Four of the 177 patients from the Amazon region had a recurrence of P. vivax parasitemia on days 21 and 28 after treatment was initiated. Two of these patients had chloroquine-resistant infections, based on polymerase chain reaction-single-stranded conformational polymorphism genotyping and chloroquine-desethylchloroquine blood levels, which were > or = 97 ng/mL at the time of the reappearance of parasitemia. None of the subjects studied on the northern Pacific Coast had recurrent parasitemia.


Subject(s)
Antimalarials/pharmacology , Chloroquine/pharmacology , Drug Resistance , Malaria, Vivax/epidemiology , Plasmodium vivax/drug effects , Adolescent , Adult , Animals , Child , Child, Preschool , DNA, Protozoan/analysis , Female , Humans , Malaria, Vivax/parasitology , Malaria, Vivax/pathology , Male , Middle Aged , Peru/epidemiology , Plasmodium vivax/genetics , Polymerase Chain Reaction , Recurrence
12.
Trop Med Int Health ; 8(10): 910-6, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14516302

ABSTRACT

Since 1994, the Peruvian Malaria Control Program has used a simplified operational approach for monitoring antimalarial drug efficacy, in which blood smears are taken 7 and 14 days after treatment from all patients diagnosed with malaria at Ministry of Health facilities. The proportion of patients with parasitaemia on one of their return visits provides an indication of the efficacy of the drug being administered. We compared this approach for antimalarial drug resistance monitoring to the more labour-intensive and expensive World Health Organization (WHO) 14-day in vivo efficacy trial at six sites in the Amazon Basin and the north coast of Peru. Although the proportion of treatment failures at 7 and 14 days identified by the operational monitoring system was considerably lower than the results of the WHO in vivo efficacy test, the operational approach did accurately reflect the overall efficacy or lack of efficacy of the drugs being evaluated. Differences in the results of the two methods were greatest in the Peruvian Amazon region, where fully supervised treatment and patient follow-up is very difficult due to the widely dispersed population. While the operational approach cannot be considered an alternative to WHO in vivo testing for evaluating the efficacy of antimalarial drugs or for recommending changes in malaria treatment policy, if treatment is supervised and follow-up blood smears taken as scheduled, this method could serve as a simple, inexpensive and sustainable early warning system for reduced drug efficacy.


Subject(s)
Antimalarials/therapeutic use , Drug Monitoring/methods , Drug Resistance , Malaria, Falciparum/drug therapy , Chloroquine/therapeutic use , Drug Combinations , Humans , Malaria, Falciparum/parasitology , Parasitic Sensitivity Tests , Peru , Pyrimethamine/therapeutic use , Quality of Health Care/standards , Sulfadoxine/therapeutic use , Treatment Failure
13.
Am J Trop Med Hyg ; 68(4): 391-7, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12875285

ABSTRACT

The World Health Organization (WHO) has developed guidelines for in vivo antimalarial drug efficacy testing for Plasmodium falciparum and Plasmodium vivax in areas with low-to-moderate transmission, such as the Americas. These guidelines are used widely by ministries of health and national malaria control programs to assess the efficacy of their first-line and second-line drugs for the treatment of malaria and to provide the information necessary to update national malaria treatment policies. Following the WHO guidelines, we have conducted in vivo efficacy trials with a variety of drugs and drug combinations against P. falciparum and P. vivax at 13 sites in Peru, Bolivia, and Ecuador. Based on these experiences, we have identified several modifications that we believe should be made in the WHO recommendations to make them more suitable to the relatively low levels of P. falciparum transmission in the Americas and to the logistic challenges of carrying out such studies in sparsely populated areas, such as the Amazon Basin. These include changes in inclusion and exclusion criteria, in enrollment and follow-up procedures, and in the measurement of study outcomes.


Subject(s)
Antimalarials/standards , Antimalarials/therapeutic use , Guidelines as Topic/standards , Malaria, Falciparum/drug therapy , Malaria, Vivax/drug therapy , Animals , Bolivia/epidemiology , Ecuador/epidemiology , Female , Follow-Up Studies , Humans , Incidence , Malaria, Falciparum/epidemiology , Malaria, Falciparum/parasitology , Malaria, Vivax/epidemiology , Malaria, Vivax/parasitology , Parasitemia/drug therapy , Parasitemia/parasitology , Patient Compliance , Patient Selection , Peru/epidemiology , Pregnancy , Recurrence , Sample Size , Time Factors , Treatment Outcome , World Health Organization
14.
Am J Trop Med Hyg ; 68(5): 608-12, 2003 May.
Article in English | MEDLINE | ID: mdl-12812355

ABSTRACT

In the Amazon Basin of Peru, more than 50% of patients with uncomplicated Plasmodium falciparum malaria fail to respond to treatment with chloroquine or sulfadoxine-pyrimethamine. To assist the National Malaria Control Program in identifying an alternative first-line therapy for this region, we conducted a trial of the safety and efficacy of mefloquine (MQ) compared with mefloquine-artesunate (MQ-AS) combination therapy. Patients with uncomplicated P. falciparum infections between the ages of 5 and 50 years were randomly assigned to be treated with either MQ (15 mg/kg in a single oral dose) or MQ (15 mg/kg) plus AS (4 mg/kg/day for three days). A total of 98 patients were enrolled and followed for 28 days. None of the 47 patients who received MQ alone or the 51 patients who received MQ-AS combination therapy had recurrences of parasitemia during the 28-day follow-up period. Asexual parasite densities decreased significantly more rapidly and the proportion of patients with gametocytes was significantly lower on days 3-21 in the MQ-AS group than in patients treated with MQ alone. All patients tolerated the medication well. Based on the results of this study and with the objective of slowing the development of resistance, the Peruvian Ministry of Health has decided to revise its malaria treatment policy and recommend combination therapy with MO-AS as the new first-line treatment of uncomplicated P. falciparum malaria in the Amazon region.


Subject(s)
Antimalarials/therapeutic use , Artemisinins/therapeutic use , Malaria, Falciparum/drug therapy , Mefloquine/therapeutic use , Sesquiterpenes/therapeutic use , Adolescent , Adult , Animals , Antimalarials/adverse effects , Artemisinins/adverse effects , Artesunate , Child , Child, Preschool , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Male , Mefloquine/adverse effects , Middle Aged , Parasitemia/drug therapy , Peru , Recurrence , Sesquiterpenes/adverse effects , Treatment Outcome , Vomiting/chemically induced
15.
Am J Trop Med Hyg ; 68(1): 120-3, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12557836

ABSTRACT

As part of an effort to assess antimalarial drug resistance in Peru, we carried out 14-day in vivo efficacy trials of chloroquine (CQ; 25 mg/kg) and sulfadoxine-pyrimethamine (SP; 25 mg/kg of the sulfadoxine component) for the treatment of uncomplicated Plasmodium falciparum infections at three sites on the northern coast of Peru. Mefloquine (MQ; 15 mg/kg) also was evaluated at one site. The results from all three sites were similar. Of the 53 patients treated with CQ, 58.5% had RII/RIII responses. No RIII failures were observed among the 112 patients who received SP, but 4.5% and 1.8%, respectively, had RII and RI responses. All 33 patients treated with MQ showed a sensitive response. Early treatment failures were observed in 27.1% of the CQ patients but in no patients receiving SP or MQ. Late treatment failures were seen in 59.3% of the CQ patients and 6.4% of the SP patients but in none of those treated with MQ. Based on these findings and because of concern about the potential for development of resistance if SP were used alone, the National Malaria Control Program is planning a change in malaria treatment policy to SP-artesunate combination therapy for this region of the country.


Subject(s)
Antimalarials/therapeutic use , Chloroquine/therapeutic use , Malaria, Falciparum/drug therapy , Mefloquine/therapeutic use , Pyrimethamine/therapeutic use , Sulfadoxine/therapeutic use , Adolescent , Adult , Animals , Antimalarials/pharmacology , Child , Child, Preschool , Chloroquine/pharmacology , Drug Combinations , Drug Resistance , Female , Humans , Male , Mefloquine/pharmacology , Middle Aged , Peru , Plasmodium falciparum/drug effects , Pyrimethamine/pharmacology , Sulfadoxine/pharmacology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...